Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1468

Shown on this page

Local recruiting

820

Top conditions

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Showing 1–12 of 1,468 matching trials with a site at Emory University (Winship Cancer Institute), Atlanta, GA.

Live ClinicalTrials.gov results.

Top conditions

Multiple Myeloma 48 Breast Cancer 30 Coronary Artery Disease 22 Prostate Cancer 19 Ovarian Cancer 17 Acute Myeloid Leukemia 16

Top therapies

Pembrolizumab 75 Carboplatin 44 Dexamethasone 43 Nivolumab 43 Cisplatin 42 Paclitaxel 42

Top lead sponsors

Emory University 198 National Cancer Institute (NCI) 133 NRG Oncology 34 Janssen Research & Development, LLC 31 ECOG-ACRIN Cancer Research Group 24 Eli Lilly and Company 24

Live official records

Conditions: Structural Heart Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Atlanta, Georgia • Bethesda, Maryland

Conditions: HIV Prevention, HIV Infection Primary
Interventions: RAMP-It-Up Initiation, Adherence, and Retention Intervention; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Jackson, Mississippi • Providence, Rhode Island

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions: LY4052031, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: HIV, PrEP, PrEP Adherence
Interventions: LYPS, Enhanced Standard of Care; Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 24 Years
Enrollment: 272 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 1 more

Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8
Interventions: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Positron Emission Tomography, Tumor Resection; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Orange, California + 8 more

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Newport Beach, California • San Francisco, California • Miami, Florida + 13 more

Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions: SESAME Procedure; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Nephropathic Cystinosis
Interventions: DFT383; Genetic
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 6
States / cities: Phoenix, Arizona • San Diego, California • Stanford, California + 3 more

Conditions: Peripheral Vascular Diseases
Interventions: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 53
States / cities: Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 42 more

Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Interventions: Pelabresib, Ruxolitinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 20
States / cities: Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 17 more

Conditions: Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 338
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 261 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 603
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 425 more

About this Emory University (Winship Cancer Institute) institution page

What this page lists: ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Emory University (Winship Cancer Institute)

Filter and sort this campus

Top conditions

Top therapies

Top lead sponsors

Live official records

NHLBI-Emory Advanced Cardiac CT Reconstruction

Intervention to Enhance PrEP Persistence

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

DFT383 in Pediatric Participants With Nephropathic Cystinosis

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

About this Emory University (Winship Cancer Institute) institution page